Matthew J. Lowe - JP Morgan Chase & Co, Research Division

It's actually Matt Lowe in for Cory today. Just to quickly come back to the partnership, to the ongoing. Just wondering, is there a certain type of deal that you are seeking, I guess, what matters most to you with the deal? Are you looking for a company that's already in diabetes care or a company with a primary care sales force? And then regarding Europe, are you looking to file yourselves there or to wait for a potential European partner to do this?

Alfred E. Mann - Founder, Chairman and Chief Executive Officer

Well, in terms of the type of company we're looking at, yes, I mean, if they do have a primary care sales force, that certainly is an advantage, an opportunity because we've seen in our market resource study, if the primary care physicians can retain their patients over a longer period time, and not to have them say, go to specialists, that is, for them, certainly a continuing care and revenue opportunity. They do not necessarily have to be, say, in insulin or in diabetes, even though some of the people we're talking to certainly are in diabetes care. In regards to the European submission, we have conducted the U.S. trials and even the ones that we are underway right now. So they will, say, very easily fit into the requirements that we would expect out of the European application. Probably the timing of a potential partnership deal will determine whether we go alone in Europe in terms of submission, say, subsequent to acceptance of our filing in the U.S. by the FDA or whether we will utilize a European partner for doing so. So I would say that's a discussion that's pending until the appropriate time.

--------------------------------------------------------------------------------------------------------------

Is it just me or would it be crazy not to make the European submission shortly after re-submitting in the US?I think it would help keep the FDA honest.They would have a lot to answer for if the European Countries were using Afrezza (and loving it) and United States citizens were denied it three times because the FDA had questions about a plastic inhaler.

Yeah or no,what do you think.